Accelr8 Technology Corporation (AMEX:AXK) announced an agreement with Becton, Dickinson (NYSE: BDX) for the BACcel™ rapid bacterial diagnostic system. Becton will fund an 18-month milestone-based project which includes the option to license the technology for product development, manufacturing and, commercialization use for the clinical diagnosis of infectious diseases. BACcel™ rapid diagnostic system may deliver bacterial identification and specific antibiotic susceptibility testing within 8 hours of specimen receipt by eliminating culturing and is based on innovative surface coatings, assay processing, and detection technologies.
Additional good news includes the issuance of Accelr8’s core Quantum Microbiology™ patent and, the acceptance of three scientific presentations for the 108th General Meeting of the American Society for Microbiology, 1-5 June, Boston. Subjects to be covered include multiplexed identification of multiple drug resistance mechanisms, rapid Acinetobacter immunoassay performance, and quantitative analysis of bacteria extracted directly from human clinical specimens.
*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!
If you enjoyed this post get free email or RSS updates (here).